Skip to main content
. 2023 Sep 21;20(1):2258850. doi: 10.1080/15502783.2023.2258850

Table 2.

Changes of between baseline and follow-up in the intervention and the control group.

Variables Vitamin D
  
   Control
  
   P valued P valuee
Month 0
 Month 1
 Changec Month 0
 Month 1
 Changec
n Mean ±SD n Mean ±SD Mean ±SD n Mean ±SD n Mean ±SD Mean ±SD
Weight and BMI 　 　 　 　 　 　 　 　 　 　 　 　
Weight, kg 56 66.77 ± 14.46 56 66.98 ± 14.63 0.21 ± 2.51 61 68.53 ± 14.54 61 68.44 ± 14.76 −0.09 ± 1.48 NS. NS.
BMI, kg/m2 56 22.01 ± 3.29 56 22.09 ± 3.41 0.08 ± 0.78 61 22.64 ± 3.01 61 22.60 ± 3.16 −0.03 ± 0.51 NS. NS.
Bone turnover 　 　 　 　 　 　 　 　 　 　 　 　
25(OH)D, ng/ml 56 18.85 ± 7.04 56 26.98 ± 5.88 8.14 ± 3.85 61 19.52 ± 8.65 61 17.61 ± 8.19 −1.91 ± 2.58 0.000 0.000
N-MID, ng/ml 56 33.61 ± 13.96 56 32.05 ± 11.60 −1.57 ± 5.57 61 30.58 ± 10.85 61 30.64 ± 10.52 0.06 ± 6.31 NS. NS.
PTH, pg/ml 56 45.76 ± 18.65 56 41.99 ± 20.92 −3.77 ± 15.71 61 50.92 ± 20.64 61 49.91 ± 19.52 −1.01 ± 23.20 0.043 NS.
Calcium, mmol/L 56 2.37 ± 0.08 56 2.37 ± 0.09 0 ± 0.11 61 2.38 ± 0.08 61 2.38 ± 0.08 −0.01 ± 0.1 NS. NS.
Erythrocytes and hemoglobin-related parameters 　 　 　 　 　 　 　 　 　 　
Hb, g/L 56 152.80 ± 15.64 56 153.88 ± 15.29 1.07 ± 11.73 61 153.95 ± 14.41 61 153.15 ± 16.49 −0.8 ± 11.68 NS. NS.
HCT, % 56 46.23 ± 4.10 56 46.56 ± 4.57 0.33 ± 3.25 61 46.23 ± 3.67 61 46.74 ± 4.56 0.51 ± 3.26 NS. NS.
RBC,10^12/L 56 5.05 ± 0.46 56 5.12 ± 0.48 0.07 ± 0.30 61 5.05 ± 0.40 61 5.14 ± 0.52 0.09 ± 0.30 NS. NS.
RDW, % 56 40.98 ± 4.85 56 40.80 ± 3.48 −0.18 ± 5.42 61 41.60 ± 2.27 61 40.94 ± 3.64 −0.67 ± 3.21 NS. NS.
Lipid metabolism 　 　 　 　 　 　 　 　 　 　 　 　
TC, mmol/L 56 4.38 ± 0.74 56 4.50 ± 0.86 0.13 ± 0.47 61 4.45 ± 0.77 61 4.68 ± 0.79 0.23 ± 0.45 NS. NS.
HDL-C, mmol/L 56 1.38 ± 0.31 56 1.37 ± 0.29 −0.01 ± 0.17 61 1.37 ± 0.32 61 1.42 ± 0.31 0.05 ± 0.18 NS. NS.
LDL-C, mmol/L 56 2.59 ± 0.67 56 2.71 ± 0.81 0.13 ± 0.43 61 2.58 ± 0.59 61 2.80 ± 0.67 0.22 ± 0.45 NS. NS.
TG, mmol/L 56 0.91 ± 0.46 56 0.93 ± 0.39 0.02 ± 0.38 61 1.09 ± 0.74 61 1.03 ± 0.45 −0.06 ± 0.70 NS. NS.
FFA, mmol/L 56 0.39 ± 0.19 56 0.44 ± 0.23 0.05 ± 0.26 61 0.38 ± 0.17 61 0.42 ± 0.27 0.05 ± 0.28 NS. NS.
Fatigue-related indicators 　 　 　 　 　 　 　 　 　 　
CK, U/L 56 276.18 ± 559.42 56 184.05 ± 195.59 −92.13 ± 558.77 61 180.38 ± 121.51 61 154.79 ± 129.25 −25.59 ± 120.76 NS. NS.
LDH, U/L 56 187.80 ± 37.77 56 173.91 ± 28.62 −13.89 ± 33.46 61 186.70 ± 30.95 61 171.44 ± 29.29 −15.26 ± 19.16 NS. NS.
T, ng/ml 56 4.29 ± 2.66 56 4.26 ± 2.67 −0.03 ± 0.95 61 3.87 ± 2.40 61 3.85 ± 2.49 −0.01 ± 0.87 NS. NS.
Physical performance 　 　 　 　 　 　 　 　 　 　 　
VJH, cm 56 39.86 ± 9.84 56 40.71 ± 10.39 0.85 ± 2.96 61 37.44 ± 11.19 61 37.82 ± 11.13 0.38 ± 3.21 NS. NS.
RHS, kg 56 413.13 ± 114.60 56 416.07 ± 118.33 2.95 ± 27.99 61 401.15 ± 111.30 61 400.98 ± 114.26 −0.16 ± 29.72 NS. NS.
FVC, L 56 4.33 ± 0.92 56 4.35 ± 0.98 0.02 ± 0.26 61 4.18 ± 1.04 61 4.17 ± 1.06 −0.01 ± 0.32 NS. NS.
FEV1, L 56 3.84 ± 0.77 56 3.85 ± 0.81 0.01 ± 0.24 61 3.78 ± 0.86 61 3.77 ± 0.89 −0.01 ± 0.28 NS. NS.

Month 0: measurements at baseline; Month 1: measurements after 1 month of intervention.

cChange = Month 1 minus Month 0.

dA repeated measure analysis of variance (ANCOVA) was used to evaluated the interaction effect for group by time.

eBetween group differences were compared using the Mann–Whitney U-test.

NS: No significant.